A Phase 1, Single Dose, 4-Period Crossover Study to Assess the Bioavailability of an Mirabegron Oral Suspension Relative to the Mirabegron Prolonged Release Tablet and to Assess the Effect of Food on the Pharmacokinetics of Mirabegron Oral Suspension in Healthy Young Male and Female Subjects
Latest Information Update: 19 Mar 2015
At a glance
- Drugs Mirabegron (Primary) ; Mirabegron (Primary)
- Indications Overactive bladder; Urination disorders
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 14 Mar 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database
- 22 Oct 2014 New trial record